Söndag 27 April | 10:42:32 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2025-05-23 08:30 Kvartalsrapport 2025-Q1
2025-05-22 N/A X-dag ordinarie utdelning CMH 0.00 SEK
2025-05-22 N/A X-dag ordinarie utdelning CMH PREF 0.00 SEK
2025-05-21 N/A Årsstämma
2025-03-28 - Bokslutskommuniké 2024
2025-01-28 - Extra Bolagsstämma 2025
2024-11-05 - Kvartalsrapport 2024-Q3
2024-08-30 - Kvartalsrapport 2024-Q2
2024-08-29 - Split CMH 500:1
2024-05-24 - Kvartalsrapport 2024-Q1
2024-05-20 - X-dag ordinarie utdelning CMH 0.00 SEK
2024-05-15 - Årsstämma
2024-03-22 - Bokslutskommuniké 2023
2024-01-26 - Extra Bolagsstämma 2024
2023-11-01 - Kvartalsrapport 2023-Q3
2023-08-31 - Kvartalsrapport 2023-Q2
2023-05-25 - Kvartalsrapport 2023-Q1
2023-04-14 - X-dag ordinarie utdelning CMH 0.00 SEK
2023-02-28 - Bokslutskommuniké 2022
2022-12-13 - Extra Bolagsstämma 2022
2022-11-18 - Kvartalsrapport 2022-Q3
2022-08-30 - Kvartalsrapport 2022-Q2
2022-05-27 - Kvartalsrapport 2022-Q1
2022-04-26 - X-dag ordinarie utdelning CMH 0.00 SEK
2022-04-25 - Årsstämma
2022-02-25 - Bokslutskommuniké 2021
2021-10-25 - Kvartalsrapport 2021-Q3
2021-10-05 - Extra Bolagsstämma 2021
2021-08-30 - Kvartalsrapport 2021-Q2
2021-05-27 - Kvartalsrapport 2021-Q1
2021-04-16 - X-dag ordinarie utdelning CMH 0.00 SEK
2021-04-15 - Årsstämma
2021-02-26 - Bokslutskommuniké 2020
2020-11-20 - Kvartalsrapport 2020-Q3
2020-08-18 - Extra Bolagsstämma 2020
2020-08-07 - Kvartalsrapport 2020-Q2
2020-04-29 - Kvartalsrapport 2020-Q1
2020-04-24 - X-dag ordinarie utdelning CMH 0.00 SEK
2020-04-23 - Årsstämma
2020-02-28 - Bokslutskommuniké 2019
2019-11-11 - Kvartalsrapport 2019-Q3
2019-08-30 - Kvartalsrapport 2019-Q2
2019-05-24 - Kvartalsrapport 2019-Q1
2019-05-10 - X-dag ordinarie utdelning CMH 0.00 SEK
2019-05-09 - Årsstämma
2019-02-28 - Bokslutskommuniké 2018
2018-11-16 - Kvartalsrapport 2018-Q3
2018-08-31 - Kvartalsrapport 2018-Q2
2018-05-25 - Kvartalsrapport 2018-Q1
2018-04-27 - X-dag ordinarie utdelning CMH 0.00 SEK
2018-04-26 - Årsstämma
2018-02-28 - Bokslutskommuniké 2017
2017-10-31 - Kvartalsrapport 2017-Q3
2017-08-31 - Kvartalsrapport 2017-Q2
2017-04-28 - Kvartalsrapport 2017-Q1
2017-04-20 - X-dag ordinarie utdelning CMH 0.00 SEK
2017-04-19 - Årsstämma
2017-02-10 - Bokslutskommuniké 2016

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Chordate Medical Holding är ett medicintekniskt bolag som har utvecklat, patenterat och CE-märkt Ozilia® Migraine, en neuromodulerande och läkemedelsfri behandlingsteknik mot kronisk migrän och kronisk rinit. Behandlingen har bevisad effekt enligt en klinisk studie och marknadsförs på utvalda marknader i EU och Mellanöstern. Bolaget har sitt huvudkontor i Kista.
2023-06-12 08:20:00

In a new interview with Biostock, principal investigator Dr. Lino Di Rienzo Businco discusses the new study titled "Effectiveness of Kinetic Oscillation Stimulation Treatment in Persistent Moderate-Severe Allergic Rhinitis Compared to Medical Therapy". The study shows that Chordate's K.O.S treatment improves nasal airflow more effectively than medical therapy alone in cases of persistent moderate to severe allergic rhinitis. Dr. Businco is an otolaryngologist, an expert in sports medicine, and has been treating patients with K.O.S for several years, including top athletes in Italy's Olympic team.

"Key take away is the capability of K.O.S to complete the effectiveness of the standard medical care for allergic rhinitis with a very effective, non-invasive treatment and high patient compliance. Nasal obstruction, runny nose, nasal discharge, itching, and sneezing are better controlled when adding  an effective treatment against neurogenic inflammation. Otherwise, symptoms are not always well controlled in this special group of patients with moderate to severe allergic rhinitis," says Dr. Businco to Biostock.

Chordate Medical has not previously investigated the effects of K.O.S on allergic rhinitis to a significant extent, which means that the study results open up new potential opportunities for the company.

"The innovative concept is that K.O.S not only has a positive effect on non-allergic patients, but even on allergic patients in an effective way to better control the symptoms and improve the efficiency of standard drugs such as nasal sprays, steroid sprays, and antihistamines, and perhaps even reduce the need for these medications with their associated side effects", says Dr. Businco.

Watch the full interview with Dr. Lino Di Rienzo Businco